Featured Article
DaVita, a kidney care provider primarily serving the United States, had a positive FY 2024. Revenue rose 5.6% to $12.8 billion, and operating profits rose 30% to $2.1 billion over last year. A review of DaVita’s 13 February 2025 earnings call and associated financial reports provided insight regarding the importance of pricing on performance. FACTS FROM EARNINGS CALL AND ANNUAL REPORT Javier Rodriguez, CEO of DaVita, sent mixed signals about revenue drivers.…
In This Issue
Edwards Lifesciences, a global leader in structural heart innovation, reported a positive FY 2024. Revenue rose 8.6% to $5.4 billion and earnings…
LabCorp, a laboratory services company for medical providers, pharmaceuticals, and researchers, had a positive FY 2024. Revenue rose 7% to $13.0 billion,…
Moderna, a leader in mRNA medicine best known for its COVID vaccine, had a mixed FY 2024. Revenue fell 53% to $3.2…
Tariffs are in the news, but will they have no to little impact on inflation? What can we expect in the next…